Haematologica最新文献

筛选
英文 中文
The real world of acute lymphoblastic leukemia. 急性淋巴细胞白血病的真实世界。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.286346
Mark R Litzow
{"title":"The real world of acute lymphoblastic leukemia.","authors":"Mark R Litzow","doi":"10.3324/haematol.2024.286346","DOIUrl":"10.3324/haematol.2024.286346","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"20-21"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets. 结节性T细胞淋巴瘤的深度表型揭示了免疫改变和治疗靶点。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2023.284448
Pierre Stephan, Jimmy Perrot, Allison Voisin, Maud Barbery, Thibault Andrieu, Maxime Grimont, Julie Caramel, Mathilde Bardou, Garance Tondeur, Edoardo Missiaglia, Philippe Gaulard, François Lemmonier, Laurence De Leval, Emmanuel Bachy, Pierre Sujobert, Laurent Genestier, Alexandra Traverse-Glehen, Yenkel Grinberg-Bleyer
{"title":"Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets.","authors":"Pierre Stephan, Jimmy Perrot, Allison Voisin, Maud Barbery, Thibault Andrieu, Maxime Grimont, Julie Caramel, Mathilde Bardou, Garance Tondeur, Edoardo Missiaglia, Philippe Gaulard, François Lemmonier, Laurence De Leval, Emmanuel Bachy, Pierre Sujobert, Laurent Genestier, Alexandra Traverse-Glehen, Yenkel Grinberg-Bleyer","doi":"10.3324/haematol.2023.284448","DOIUrl":"10.3324/haematol.2023.284448","url":null,"abstract":"<p><p>Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a lack of understanding of the immune response they trigger. To fully characterize the immune tumor microenvironment (TME) of PTCL, we performed spectral flow cytometry analyses on 11 angioimmunoblastic T-cell lymphomas (AITL), 7 PTCL, not otherwise specified (PTCL, NOS) lymph node samples, and 10 non-tumoral control samples. The PTCL TME contained a larger proportion of regulatory T cells and exhausted CD8+ T cells, with enriched expression of druggable immune checkpoints. Interestingly, CD39 expression was up-regulated at the surface of most immune cells, and a multi-immunofluorescence analysis on a retrospective cohort of 43 AITL patients demonstrated a significant association between high CD39 expression by T cells and poor patient prognosis. Together, our study unravels the complex TME of nodal PTCL, identifies targetable immune checkpoints, and highlights CD39 as a novel prognostic factor.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"129-141"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting. 基于 Venetoclax 的急性髓性白血病治疗中的预后分层:在真实世界环境中测试的分子预后风险特征。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285934
Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I Vanderwert, Paola Guglielmelli, Alessandro M Vannucchi
{"title":"Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.","authors":"Gaia Ciolli, Matteo Piccini, Francesco Mannelli, Giacomo Gianfaldoni, Barbara Scappini, Laura Fasano, Francesca Crupi, Elisa Quinti, Andrea Pasquini, Jessica Caroprese, Giada Rotunno, Fabiana Pancani, Leonardo Signori, Chiara Maccari, Fiorenza I Vanderwert, Paola Guglielmelli, Alessandro M Vannucchi","doi":"10.3324/haematol.2024.285934","DOIUrl":"10.3324/haematol.2024.285934","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"239-243"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting. LIPA-frogging爆发期慢性髓性白血病:利用溶酶体靶向克服耐药性。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.286140
Miguel Quijada-Álamo, Grace Freed, Elvin Wagenblast
{"title":"LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting.","authors":"Miguel Quijada-Álamo, Grace Freed, Elvin Wagenblast","doi":"10.3324/haematol.2024.286140","DOIUrl":"10.3324/haematol.2024.286140","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"13-15"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes. 苯达莫司汀治疗滤泡性淋巴瘤和套细胞淋巴瘤后,利妥昔单抗的维持治疗可能对SARS-CoV-2感染的结果产生负面影响。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285219
Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez-Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta
{"title":"Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes.","authors":"Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez-Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta","doi":"10.3324/haematol.2024.285219","DOIUrl":"10.3324/haematol.2024.285219","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"173-178"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.286063
Yishai Ofran, Jacob M Rowe
{"title":"Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia - the CONS.","authors":"Yishai Ofran, Jacob M Rowe","doi":"10.3324/haematol.2024.286063","DOIUrl":"10.3324/haematol.2024.286063","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"110 1","pages":"7-10"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma. 阿特珠单抗联合免疫原性挽救化疗免疫疗法治疗转化型弥漫大B细胞淋巴瘤患者。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285185
Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera
{"title":"Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.","authors":"Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T Rosen, Elad Sharon, Miguel Villalona-Calero, Christopher Ruel, Joseph Tuscano, Alex F Herrera","doi":"10.3324/haematol.2024.285185","DOIUrl":"10.3324/haematol.2024.285185","url":null,"abstract":"<p><p>Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) transformed from indolent B-cell lymphomas, including Richter transformation, have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates in B-cell non-Hodgkin lymphoma as monotherapy but may synergize with immunogenic chemotherapies such as gemcitabine and oxaliplatin (GemOx). Thus, we evaluated the safety and efficacy of atezolizumab plus rituximab and GemOx (R-GemOx+Atezo) in R/R transformed DLBCL, including Richter transformation. We conducted a phase I trial including patients with transformed DLBCL after ≥1 prior therapy. Patients received up to four cycles of R-GemOx+Atezo. Patients in complete remission could then proceed to R-Atezo maintenance until progression. A safety lead-in with evaluation of dose-limiting toxicity was performed to confirm the recommended phase II dose; subsequently the treatment was administered to two expansion cohorts: one with transformed follicular lymphoma (FL) and the other with non-FL transformed DLBCL, including Richter transformation. Twenty-seven patients were enrolled. One of the six patients in the safety lead-in had a dose-limiting toxicity attributed to atezolizumab, a grade 4 Stevens-Johnson syndrome. The most common grade ≥3 events were neutropenia (18.5%), lymphopenia (18.5%), and thrombocytopenia (14.8%). The overall and complete response rates were 59% and 33%, respectively. The overall and complete response rates in transformed FL were 79% and 43%, respectively, and 38% and 23% in transformed non-FL, respectively. The median progression-free survival and overall survival of the total population were 4.2 and 7.7 months, respectively. R-GemOx+Atezo was well tolerated and demonstrated promising preliminary efficacy in patients with relapsed/refractory transformed DLBCL.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"142-152"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemia. 在急性髓性白血病的实验模型中,Cd39 和 P2rx7-Wnt 信号增强了胚泡的致病性。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285547
Lili Feng, Haohai Zhang, Changchuin Mao, Paola De Andrade Mello, Dina Stroopinsky, Eva Csizmadia, Jialin Zhou, David Avigan, Jinming Yu, Wenda Gao, Simon C Robson
{"title":"Cd39 and P2rx7-Wnt signaling enhance blast pathogenicity in an experimental model of acute myeloid leukemia.","authors":"Lili Feng, Haohai Zhang, Changchuin Mao, Paola De Andrade Mello, Dina Stroopinsky, Eva Csizmadia, Jialin Zhou, David Avigan, Jinming Yu, Wenda Gao, Simon C Robson","doi":"10.3324/haematol.2024.285547","DOIUrl":"10.3324/haematol.2024.285547","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"212-217"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. 比较多发性骨髓瘤治疗方法的临床试验疗效与实际疗效:一项基于人群的研究。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285768
Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Arleigh McCurdy, Irwindeep Sandhu, Christopher Venner, Guido Lancman, Amaris Balitsky, Tom Kouroukis, Robert Bruins, Shaji Kumar, Rafael Fonseca, Hira Mian
{"title":"Comparing the clinical trial efficacy <i>versus</i> real-world effectiveness of treatments for multiple myeloma: a population-based study.","authors":"Alissa Visram, Kelvin Kar-Wing Chan, Hsien Seow, Gregory Pond, Anastasia Gayowsky, Ghulam Rehman Mohyuddin, Arleigh McCurdy, Irwindeep Sandhu, Christopher Venner, Guido Lancman, Amaris Balitsky, Tom Kouroukis, Robert Bruins, Shaji Kumar, Rafael Fonseca, Hira Mian","doi":"10.3324/haematol.2024.285768","DOIUrl":"10.3324/haematol.2024.285768","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"228-233"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of human apotransferrin infusion in patients with β-thalassemia intermedia: the AIM study. 人源转铁蛋白输注对中型β地中海贫血患者的安全性和有效性:AIM 研究。
IF 8.2 1区 医学
Haematologica Pub Date : 2025-01-01 DOI: 10.3324/haematol.2024.285045
Kadère Konté, Dorine W Swinkels, Ilona Kleine Budde, Erfan Nur, Bart J Biemond
{"title":"Safety and efficacy of human apotransferrin infusion in patients with β-thalassemia intermedia: the AIM study.","authors":"Kadère Konté, Dorine W Swinkels, Ilona Kleine Budde, Erfan Nur, Bart J Biemond","doi":"10.3324/haematol.2024.285045","DOIUrl":"10.3324/haematol.2024.285045","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"183-186"},"PeriodicalIF":8.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信